A Study of Sacituzumab Govitecan (IMMU-132) in Platinum-resistant Ovarian Cancer Patients
This is a non-randomized Phase 2 study of sacituzumab govitecan (IMMU-132) in subjects with recurrent or persistent platinum-resistant epithelial ovarian, fallopian tube, or primary peritoneal cancers.
Ovarian Carcinoma
DRUG: Sacituzumab govitecan
Objective Response Rate (ORR), Objective response rate (complete response and partial response rates) by RECIST1.1 criteria in patients with platinum resistant recurrent ovarian carcinoma., 4 Years
Duration of overall survival (OS), Overall survival is defined as the duration of time from study entry to death or the date of last contact., 6 Years|Duration of progression free survival (PFS), Progression free survival is defined as the duration of time from study entry to time of progression, death, or is censored at date of last disease assessment, 6 Years|Durable disease control rate (DDCR), The percentage of patients who have achieved complete response, partial response, and stable disease., 6 Years|Assess the safety profile of sacituzumab govitecan in ovarian cancer patients (adverse events as assessed by CTCAE v5.0), Incidence of treatment-related adverse events as assessed by Common Terminology Criteria for Adverse Events (CTCAE) v5.0, 6 Years
This is an open-label, Phase 2 study designed to assess the clinical activity of sacituzumab govitecan in subjects with recurrent or persistent platinum-resistant epithelial ovarian, fallopian tube, or primary peritoneal cancers.